GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maxygen, Inc. (FRA:MYN) » Definitions » Other Income (Minority Interest)

Maxygen, (FRA:MYN) Other Income (Minority Interest) : €0.00 Mil (TTM As of Mar. 2013)


View and export this data going back to . Start your Free Trial

What is Maxygen, Other Income (Minority Interest)?

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary. Maxygen,'s Other Income (Minority Interest) for the three months ended in Mar. 2013 was €0.00 Mil. Its Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Mar. 2013 was €0.00 Mil.


Maxygen, Other Income (Minority Interest) Historical Data

The historical data trend for Maxygen,'s Other Income (Minority Interest) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxygen, Other Income (Minority Interest) Chart

Maxygen, Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Other Income (Minority Interest)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Maxygen, Quarterly Data
Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13
Other Income (Minority Interest) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Maxygen, Other Income (Minority Interest) Calculation

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary.

Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Mar. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maxygen,  (FRA:MYN) Other Income (Minority Interest) Explanation

Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company. It is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


Maxygen, (FRA:MYN) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Website
Maxygen, Inc., is incorporated in Delaware. It is a biotechnology company. It discovers and develops improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. The Company's MAXY-G34 product candidate has been designed to be an improved next-generation pegylated, G-CSF for the treatment of chemotherapy-induced neutropenia. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The Company completed a Phase IIa clinical trial for its MAXY-G34 product candidate for the treatment of chemotherapy-induced neutropenia in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia with no serious adverse events, drug-related grade 3 or 4 adverse events or immunogenicity reported in any patient receiving MAXY-G34. Adverse events were consistent with known side effects of G-CSF molecules. The Company is subject to regulation by the FDA and comparable regulatory agencies in foreign countries with respect to any development and commercialization of its MAXY-G34 product candidate or any other products it may acquire in the future.

Maxygen, (FRA:MYN) Headlines